ACADIA to Host Conference Call and Webcast on Wednesday, August 5, 2009, at 5:00 p.m. Eastern Time SAN DIEGO—(BUSINESS WIRE)—Jul. 29, 2009—ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD), a biopharmaceutical companyutilizing innovative technology to fuel drug discovery and clinicaldevelopment of novel treatments for central nervous system disorders,today announced that it will report its unaudited financial results forthe second quarter ended June 30, 2009 on Wednesday, August 5, 2009,after the U.S. financial markets close. ACADIA's management will host aconference call and webcast on Wednesday, August 5, 2009, at 5:00 p.m.Eastern Time to discuss ACADIA’s financial results and developmentprograms.
The conference call may be accessed by dialing 866-831-6234 forparticipants in the U.S. or Canada and 617-213-8854 for internationalcallers (reference passcode 31522932). A telephone replay of theconference call may be accessed through August 19, 2009 by dialing888-286-8010 for callers in the U.S. or Canada and 617-801-6888 forinternational callers (reference passcode 97036682). The conference callalso will be webcast live on ACADIA’s website, www.acadia-pharm.com,under the investors section and will be archived there until August 19,2009.
About ACADIA Pharmaceuticals
ACADIA is a biopharmaceutical company utilizing innovative technology tofuel drug discovery and clinical development of novel treatments forcentral nervous system disorders. ACADIA is currently developing aportfolio consisting of its five most advanced product candidatesincluding pimavanserin, which is in Phase III development forParkinson’s disease psychosis in collaboration with Biovail. In additionto pimavanserin, ACADIA has a product candidate in Phase II for chronicpain and a product candidate in Phase I for glaucoma, both incollaboration with Allergan, as well as two programs in IND-trackdevelopment. All of the product candidates in ACADIA’s pipeline emanatefrom discoveries made using its proprietary drug discovery platform.ACADIA maintains a website at www.acadia-pharm.comto which ACADIA regularly posts copies of its press releases as well asadditional information and through which interested parties cansubscribe to receive email alerts.
Source: ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc.
Lisa Barthelemy, Director,Investor Relations
Thomas H. Aasen, Vice President and ChiefFinancial Officer
(858) 558-2871